Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
1. A method of treating a disease selected from ulcerative colitis and Crohn's disease in a patient in need thereof, comprising administering to the patient a compound, which is 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, wherein the treating refers to ameliorating or inhibiting ulcerative colitis and Crohn's disease in the patient.
2. The method of claim 1 , wherein the disease is ulcerative colitis.
3. The method of claim 1 , wherein the disease is Crohn's disease.
4. The method of claim 2 , wherein the compound is (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof.
5. The method of claim 2 , wherein the compound is (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile.
6. The method of claim 3 , wherein the compound is (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof.
7. The method of claim 3 , wherein the compound is (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile.
8. The method of claim 2 , wherein the compound is (3S)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof.
9. The method of claim 2 , wherein the compound is (3S)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile.
10. The method of claim 3 , wherein the compound is (3S)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof.
11. The method of claim 3 , wherein the compound is (3S)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile.
12. The method of claim 2 , wherein said administering comprises administering a pharmaceutical composition comprising the compound, or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
13. The method of claim 3 , wherein said administering comprises administering a pharmaceutical composition comprising the compound, or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
14. The method of claim 4 , wherein said administering comprises administering a pharmaceutical composition comprising the compound, or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
15. The method of claim 5 , wherein said administering comprises administering a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.
16. The method of claim 6 , wherein said administering comprises administering a pharmaceutical composition comprising the compound, or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
17. The method of claim 7 , wherein said administering comprises administering a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.
18. The method of claim 8 , wherein said administering comprises administering a pharmaceutical composition comprising the compound, or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
19. The method of claim 9 , wherein said administering comprises administering a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.
20. The method of claim 10 , wherein said administering comprises administering a pharmaceutical composition comprising the compound, or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
21. The method of claim 11 , wherein said administering comprises administering a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.